Treatment of Extrapulmonary Tuberculosis

Standard Drug-Susceptible Regimen

• The American Academy of Family Physicians recommends a standard 6-month regimen of isoniazid, rifampin, pyrazinamide, and ethambutol for 2 months, followed by isoniazid and rifampin for 4 months for drug-susceptible extrapulmonary TB 1
• The American Academy of Family Physicians suggests that ethambutol can be omitted if drug susceptibility testing confirms no isoniazid resistance and community resistance rates are <4% 1

Critical Site-Specific Considerations

• The American College of Physicians recommends 9-18 months of treatment for TB osteoarticular disease depending on severity and response 2
• For TB meningitis, miliary TB, or bone/joint involvement, treatment should be extended to 9-12 months 2

Drug-Resistant Extrapulmonary TB

• For isoniazid-resistant, rifampin-susceptible disease, a 6-month regimen of rifampin, ethambutol, pyrazinamide, and a later-generation fluoroquinolone (levofloxacin preferred over moxifloxacin) is recommended 2, 4
• For MDR/RR-TB, a first-line approach with the BPaLM regimen (bedaquiline, pretomanid, linezolid, moxifloxacin) for 6 months is recommended if no documented fluoroquinolone or bedaquiline resistance exists 4, 5

Essential Management Principles

• The Centers for Disease Control and Prevention strongly recommends directly observed therapy for all TB patients to ensure adherence and prevent resistance 3, 4
• Monthly sputum cultures should be monitored until negative, and patients should be instructed to report any symptoms of hepatotoxicity 3, 5
• The American Thoracic Society advises against adding a single drug to a failing regimen, as this can rapidly lead to acquired resistance 2, 6